Japan Pharmaceutical Market Outlook New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players

  • 78 views
Uploaded on

Buy the report "Japan Pharmaceutical Market Outlook – Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Playersh" at US …

Buy the report "Japan Pharmaceutical Market Outlook – Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Playersh" at US $3500 for a Single User PDF License from RnR Market Research Reports Library.“Japan Pharmaceutical Market Outlook – Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players”. Japan’s pharmaceutical industry is the second largest in the world, worth $89 billion in 2011 or 10% of the world market.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
78
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
1
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. RnR Market Research Offers “Japan Pharmaceutical Market Outlook – Deregulation andMore Efficient New Drug Approval Process Attract Foreign Investment and Improve theCompetitiveness of Japanese Players” Report at US$ 3500 Single User License. Thereport got published in Apr 2013 Contain 97 Pages.The Declining and Rapidly Aging Population Presents Significant Challenges to the Healthcare Systemand Economy as a WholeJapan had a population of 127,817,277 in 2011, making it the 10th most populated country in the world(The World Bank, 2012). However, since 2005, as the number of deaths exceeded that of births, thepopulation has declined. Without significant government intervention, the depopulation process isexpected to continue.The proportion of people aged 65 or over is 23.3% and projected to reach 29.1% by 2020 and almost40% by 2050 (Statistical Research and Training Institute, 2012).These demographic changes will present further challenges to a stagnating economy, which, as the datain this report confirms, is already struggling with reduced economic growth. A diminishing workforce andfalling productivity levels will likely add to the economic difficulties Japan is experiencing.The associated increase in disease burden has also had implications for the healthcare system.Healthcare expenditure has risen, and is set to rise further as the population continues to age.Get Report Details @ http://www.rnrmarketresearch.com/japan-pharmaceutical-market-outlook-deregulation-and-more-efficient-new-drug-approval-process-attract-foreign-investment-and-improve-the-competitiveness-of-japanese-players-market-report.htmlIn 2010, Japan’s healthcare spending per capita was $4,065.4, a significant increase from 2005.Japan’s universal healthcare system may therefore prove unsustainable as the government looks tocontrol spending. A combination of pro-generic policies, government initiatives to prevent lifestylediseases, and higher copayments should help to keep healthcare expenditure under control.Regulatory Reform will Continue to Attract Foreign Pharmaceutical CompaniesThe ongoing deregulation of the Japanese pharmaceutical industry has made it an attractive market forbig pharma. Improvements to the new drug approval process have significantly shortened the approvaltime. Consultation services provided by approval bodies have been expanded and improved, approvalstandards have been clarified and the number of trained personnel involved in the review process hasincreased.Many of these changes have occurred following the introduction of a number of plans and governmentpolicies. Plans are currently being implemented to shorten the review period and improve cooperationwith other countries, particularly Western and other Asian nations, such as the Second Medium RangePlan (2009–2014), which includes the International Strategic Plan.Request a Sample Copy @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=92373
  • 2. In April 2007, the government introduced the 5-Year Strategy for the Creation of InnovativePharmaceuticals and Medical Devices, which contributed towards the reduction in lag time associatedwith new product approvals.In addition to attracting foreign investment, deregulation has also improved the competitiveness ofJapan’s pharmaceutical companies. The market now consists of multinational players such as Takedaand Daiichi Sankyo, who market leading products globally.Takeda Maintains its Position as the Leading Company in the Japanese Pharmaceutical IndustryTakeda maintained its position as the leader in Japan’s pharmaceutical industry in 2012, with revenues of$18.9 billion. This was followed by Otsuka Holdings, Astellas, Daiichi Sankyo and Eisai.M&A activity has become a common theme within the global pharmaceutical industry. This is often astrategic response to patent expirations, reduced R&D productivity and the need to cut costs.The Japanese pharmaceutical industry has followed this trend. Although historically dependent ondomestic R&D, the recent globalization of Japanese companies has been driven by enhanced M&Aactivity. Significant deals have been completed in the US, Europe and developing nations, such as China,India and Brazil.With a total of 20 M&A, including two recently announced, Takeda has been the most active Japanesecompany.The M&A strategy is seen as necessary for pharmaceutical companies keen to expand product pipelinesfollowing patent expirations and gain access to untapped markets. It is hoped that such strategicmeasures will help develop or maintain growth and revenue.Reasons to buy- Primarily, the report will allow clients to gain a strong understanding of the economic and healthcarechallenges facing Japan.- In addition, the report will assist in identifying opportunities within Japan’s pharmaceutical market,including:- Potential for market growth – A number of factors could provide strong potential for sales growth in theJapanese pharmaceutical market. Examples include the world leading life expectancy and associatedincrease in lifestyle diseases, and government initiatives to prevent such diseases, which providesopportunities for healthcare and pharmaceutical companies, who often carry out the work.- The report provides a source of information covering Japan’s regulatory landscape, and importantly,recent deregulation, to help identify the reasons Japan has become an attractive market for big pharma.- The report will provide new market entrants with a comprehensive overview of the leading Japanesepharmaceutical companies, and the specific therapeutic indications they are currently targeting.- Overall, allowing clients to determine whether the Japanese pharmaceutical market will provide themwith commercially viable opportunities for growth.Buy a Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=92373Table of Content1 Table of Contents 61.1 List of Tables 81.2 List of Figures 82 Introduction 10
  • 3. 3 Market Overview 113.1 Introduction 113.2 Economic Landscape 113.3 Economic Indicators 123.3.1 Gross Domestic Product 123.3.2 GDP Composition by Sector 153.3.3 Consumer Price Index 163.3.4 Unemployment 183.3.5 Exchange Rate 203.3.6 Foreign Direct Investment 213.3.7 Trade Balance 233.3.8 Value of Exports/Imports 243.3.9 Exports and Imports Forecast 253.3.10 Trading Partners 263.3.11 Government Debt 273.3.12 Gross National Income 283.3.13 Gross National Savings 313.3.14 Labor Force 323.3.15 Employment 343.3.16 Current Account Balance 363.3.17 Foreign Exchange Reserves 373.4 Demographic Analysis 383.4.1 Population 383.4.2 Population Distribution 393.4.3 Urban-Rural Share 403.5 Healthcare 413.5.1 Healthcare Expenditure 413.5.2 Public and Private Expenditure 433.5.3 Healthcare Infrastructure 463.5.4 Alcohol Consumption 493.5.5 Tobacco Consumption 503.5.6 Obesity 523.5.7 Life Expectancy 533.5.8 Leading Causes of Death 543.5.9 Pharmaceutical Expenditure 553.5.10 Insurance and Reimbursement 553.5.11 Reimbursement Process 573.6 Market Segments 583.6.1 Generics 583.6.2 Over-the-Counter Drugs 594 Industry Characteristics 604.1 Introduction 604.2 Pricing Policy 604.2.1 Reimbursement Prices for New Drugs 604.3 Regulatory Landscape 624.3.1 Pharmaceutical and Food Safety Bureau 644.3.2 Pharmaceutical and Medical Devices Agency 654.3.3 New Drug Approval Process 664.3.4 Drug Manufacture 684.3.5 Clinical Trials - Basic Requirements 684.3.6 Advertising 684.3.7 Licensing 69
  • 4. 4.3.8 Orphan Drugs 694.4 Pharmaceutical Supply Chain 704.4.1 Leading Companies 715 Competitive Landscape 725.1 Introduction 725.2 Major Domestic Companies 725.2.1 Major Players by Revenue 725.2.2 Takeda 735.2.3 Product Portfolio 735.2.4 Research and Development 735.2.5 Otsuka 765.2.6 Product Portfolio 765.2.7 Research and Development 775.2.8 Astellas 785.2.9 Product Portfolio 795.2.10 Research and Development 805.2.11 Daiichi Sankyo 815.2.12 Product Portfolio 815.2.13 Research and Development 825.2.14 Eisai 835.2.15 Research and Development 845.3 Major Foreign Players 855.4 Acquisitions and Collaboration 865.4.1 M&A 865.4.2 Licensing Agreements and Co-development Deals 896 Drivers and Barriers 926.1 Drivers 926.1.1 World-Leading Life Expectancy - Increased Disease Burden 926.1.2 Deregulation - Easing of Regulatory Guidelines 926.1.3 Government Initiatives to Prevent Lifestyle Diseases 926.1.4 Continued Growth of the Generics Market 926.2 Barriers 936.2.1 Time Lag in Drug Approval Process 936.2.2 Political Instability 936.2.3 High Cost of Clinical Trials 936.2.4 High Value of the Yen 937 Japan Pharmaceutical Market Outlook - Appendix 947.1 Market Definitions 947.2 Abbreviations 947.3 Bibliography 957.4 Research Methodology 967.5 Coverage 967.6 Secondary Research 977.7 Competitive Landscape 977.7.1 Expert Panel Validation 977.8 Contact Us 977.9 Disclaimer 97For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441Website: http://www.rnrmarketresearch.com